Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLiyun ZhaoGBGuanchen BaiYBYanliang Bai

Discussion

Loading...

Member takes

Overview

Induction treatment combines venetoclax and decitabine, improving outcomes in TP53-mutant acute myeloid leukemia patients.

Key Points

  • This research aims to evaluate the efficacy and safety of venetoclax combined with three-day decitabine in AML patients with TP53 mutation.
  • Induction therapy with venetoclax and decitabine for de novo AML patients with TP53 mutation.
  • Patients received venetoclax orally and decitabine intravenously as part of the treatment regimen.
  • Outcomes measured included overall response rate, complete remission, and overall survival.
  • The overall response rate after treatment was 78.26% among participants.
  • 73.9% achieved complete remission or incomplete hematologic recovery after one cycle.
  • Most patients experienced severe hematologic toxicity, including febrile neutropenia.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da54https://doi.org/10.1182/blood-2025-3395
View Full Paper
Ask AI
Bookmark
Share